News | February 02, 2024
Vimta Labs posts Q3 FY24 consolidated PAT at Rs. 10.13 Cr
Vimta Labs has reported total income of Rs. 82.57 crores during the period ended December 31, 2023
Vimta Labs has reported total income of Rs. 82.57 crores during the period ended December 31, 2023
Morepen Laboratories has reported total income of Rs. 448.62 crores during the period ended December 31, 2023
Exblifeb demonstrates remarkable efficacy in treating complicated Urinary Tract Infections (cUTI), pneumonia
Sun Pharmaceutical Industries has reported total income of Rs. 12,630.9 crores during the period ended December 31, 2023
Submission to be reviewed under FDA real-time oncology review and Project Orbis
Union Ayush Minister with Assam Chief Minister lays foundation stone for Central Research Institute of Yoga & Naturopathy
Combines biocompatibility, heat-resistance, transparency and durability
Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival
Keynote -564 is the first Phase 3 trial to demonstrate superior overall survival (OS) with adjuvant therapy compared to placebo in patients with RCC
Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America
Subscribe To Our Newsletter & Stay Updated
